首页> 美国卫生研究院文献>BMJ Open Access >Extended report: Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised double-blind parallel-group phase III trial

【2h】

Extended report: Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised double-blind parallel-group phase III trial

机译：扩展报告：sarilumab单药和阿达木单抗单药治疗活动性类风湿关节炎（MONARCH）的疗效和安全性：一项随机双盲平行组III期临床试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectivesTo compare efficacy and safety of sarilumab monotherapy with adalimumab monotherapy in patients with active rheumatoid arthritis (RA) who should not continue treatment with methotrexate (MTX) due to intolerance or inadequate response.

机译：目的比较沙利鲁单抗单药和阿达木单抗单药治疗因不耐受或反应不足而不应继续接受甲氨蝶呤（MTX）治疗的活动性类风湿关节炎（RA）患者的疗效和安全性。

著录项

期刊名称 BMJ Open Access
作者
Gerd R Burmester; Yong Lin; Rahul Patel; Janet van Adelsberg; Erin K Mangan; Neil M H Graham; Hubert van Hoogstraten; Deborah Bauer; Juan Ignacio Vargas; Eun Bong Lee;
展开▼
作者单位

展开▼
年(卷),期 -1(76),5
年度 -1
页码 840–847
总页数 8
原文格式 PDF
正文语种
中图分类
关键词
Rheumatoid Arthritis Treatment DMARDs (biologic);

机译：类风湿关节炎;治疗;DMARD（生物）;

相似文献

外文文献
中文文献

1. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial [J] . Burmester Gerd R., Lin Yong, Patel Rahul, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2017,第5期

机译：Sarilumab单药治疗的疗效和安全性与Adalimalab单一治疗有活性类风湿性关节炎患者（君主）：随机，双盲，平行组III试验
2. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naive patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study [J] . Taylor Peter C., Schiff Michael H., Wang Qingmin, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2018,第5期

机译：与Sirukumab的单药治疗与活性类风湿性关节炎（Sirround-H）的患者单药草（Sirround-H）的疗效和安全性（Sirround-H）：随机，双盲，并联，跨国，52周，第3期研究
3. Efficacy and Safety of Switching from Adalimumab to Sarilumab in an Open-label Extension of a Phase 3 Monotherapy Trial in Patients with Active Rheumatoid Arthritis [J] . Burmester Gerd, Fiore Stefano, Hu Chih-Chi, The Journal of rheumatology . 2018,第7期

机译：从活性类风湿性关节炎患者的3阶段单药治疗的开放标签扩展中从Adalimumab切换到Sarilumab的疗效和安全性
4. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis [O] . Vibeke Strand, Laure Gossec, Clare W. J. Proudfoot, 2018

机译：类风湿关节炎患者的sarilumab单药治疗与adalimumab单药治疗的随机III期试验的患者报告结果
5. Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study) [O] . E. L. Nasonov, M. L. Stanislav, T. A. Raskina, 2019

机译：Sarilumab与甲氨蝶呤在有活性类风湿性关节炎患者中的疗效和安全性和甲氨蝶呤单疗法的疗效（III期迁移率研究的结果）

Extended report: Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised double-blind parallel-group phase III trial

摘要

著录项

相似文献

相关主题

期刊订阅